Mark Clemons - Concepedia

Author

Mark Clemons

Also Known As

Clemons, Mark, M Clemons, M J Clemons, M. Clemons, M. J. Clemons, M.J. Clemons, MARK CLEMONS, Mark Clemons, Mark J Clemons, Mark J. Clemons

295

Publications

8.2K

Citations

H-Index

102

Concepts

All Affiliations

Ottawa Hospital University of Ottawa Princess Margaret Cancer Centre Ottawa Hospital Research Institute University of Toronto

About

Mark Clemons is an author at Ottawa Hospital specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	54	3K
2	Health Sciences	14	18	1.4K
3	Public Health	3	3	138
4	Nursing	1	1	21
5	Social Sciences	1	1	52

Mark Clemons

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial José Baselga, Seock‐Ah Im, Hiroji Iwata, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyClinical TrialsGynecology	2017	532
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Christine Simmons, Naomi Miller, William R. Geddie, Annals of Oncology	2009	282
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 Susan Ellard, Mark Clemons, Karen A. Gelmon, Journal of Clinical Oncology	2009	260
Palliative Treatment of Painful Bone Metastases with MR Imaging–guided Focused Ultrasound David Gianfelice, Gupta Chander, Walter Kucharczyk, Radiology	2008	222
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting George Dranitsaris, Alex Molassiotis, Mark Clemons, Annals of Oncology	2017	217
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Rebecca Dent, Geoffrey J. Lindeman, Mark Clemons, Breast Cancer Research	2013	183
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Catherine Van Poznak, Mark R. Somerfield, William E. Barlow, Journal of Clinical Oncology Breast OncologyPain MedicinePharmacotherapyOrthopaedic SurgeryBone Disease	2017	174
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies Eitan Amir, Mark Clemons, Colin A. Purdie, Cancer Treatment Reviews Surgical OncologyBreast OncologyBreast Cancer PatientsCancer ScreeningCancer Recurrence	2011	171
Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes Sébastien Tabariès, Fanny Dupuy, Zhifeng Dong, Molecular and Cellular Biology Breast OncologyPathologyCancer BiologyTumor BiologyTumor Cell Interactions	2012	144
Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy Mark Clemons, George Dranitsaris, Wei Ooi, Journal of Clinical Oncology	2006	142

Page 1